Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory [Yahoo! Finance]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Yahoo! Finance
Syndax Pharmaceuticals, Inc.'s share was trading at $20.67 as of January 15th. Phovoir/Shutterstock.com Syndax Pharmaceuticals has transitioned into a commercial-stage biotech anchored by two first-in-class approved therapies, Revuforj (revumenib) and Niktimvo (axatilimab), each addressing areas of high unmet medical need. Revuforj is an oral Menin inhibitor approved for relapsed or refractory acute leukemias with KMT2A rearrangements, where disruption of the Menin–KMT2A interaction shuts down oncogenic gene expression and drives leukemic cell differentiation and death. Building on this approval, Syndax is pursuing expansion into NPM1-mutant AML via a supplemental NDA supported by AUGMENT-101 data, while also advancing frontline combination studies that could meaningfully broaden its addressable market. Niktimvo, an anti-CSF-1R monoclonal antibody approved for heavily pretreated chronic graft-versus-host disease, targets macrophage-driven inflammation and fibrosis, offering a di
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SNDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.GlobeNewswire
- Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
SNDX
Earnings
- 11/3/25 - Beat
SNDX
Sec Filings
- 1/12/26 - Form 8-K
- 12/19/25 - Form 8-K
- 12/1/25 - Form 4
- SNDX's page on the SEC website